BCL2L1 and lymphoma: Although this effect was less impressive compared to lymphoma and leukemia cells, it could have implications in the therapeutic window of the peptides, as was observed for the dual Bcl-2/Bcl-XL inhibitor ABT-737 and its orally bioavailable equivalent ABT-263 (Navitoclax), that showed thrombocytopenia due to inhibition of Bcl-XL [84].